19 02 2016

Lanstead Capital invests £4.4 Million in ImmuPharma plc

Cooley advised Lanstead Capital on its £4.4 million investment in AIM listed ImmuPharma PLC.


Lanstead Capital is a specialist international investment firm that provides equity capital to companies already listed on public markets. The Firm, led by Mark W. Holden, was founded in 2007 and is based in United Kingdom. ImmuPharma PLC is a specialist drug recovery and development company. The company is focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. Lupuzor is the company's most advanced drug candidate and is a treatment for lupus, and life threatening auto immune disease. Ed Lukins (Picture), corporate partner at Cooley's London Office, advised Lanstead Capital. Involved fees earner: Ed Lukins - Cooley LLP;

IAIR TV

see all videos

LATEST ISSUE
Powered by Share Trading

Everlasting
POPULAR ARTICLES
Le Fonti IAIR Awards Take Hong Kong By Storm

21/03/2017

Hong Kong has become a city of bright expansion, culture, and futuristic innovation. Fr

Will Brexit break London's place as FinTech Capital?

17/11/2016

Fintech, it’s described as the disruption in financial services pushed by consume

Le Fonti IAIR Awards 2016 celebrates excellences in London.

17/10/2016

On October 14th, 2016, the world’s leading corporate stars aligned for a momentou

IAIR AWARDS 2016 IN NEW YORK: EMONEY ADVISOR, C.A.S.H., CREDIT SUISSE AND CHEETAH MOBILE AMONG THE WINNERS

15/04/2016

More than 19 Excellences in the global economy at the VI Annual Edition of IAIR AWARDS&

IAIR AWARDS & CEO SUMMIT 2015 IN DUBAI

20/11/2015

It took place on 19 November 2015 at Palace Downtown in Dubai the 19th edition of the I